References
- Bailey JA (1988). Concise dictionary of medical-legal terms. New York, The Parthanon Publishing Group.
- Berger MS, Locher GW, Saurer S, et al (1988). Correlation of c-erb B2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res, 48, 1238-43.
- Chuangsuwanich T, Pongpruttipan T, O-Charoenrat P, et al (2014). Clinicopathologic features of breast carcinomas classified by biomarkers and correlation with microvessel density and VEGF expression: a study from Thailand. Asian Pac J Cancer Prev, 15, 1187-92. https://doi.org/10.7314/APJCP.2014.15.3.1187
- Dawood S, Broglio K, Buzdar AU, et al (2010). Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol, 28, 92-8. https://doi.org/10.1200/JCO.2008.19.9844
- Dorr FA (1993). Prognostic Factors Observed in Current Clinical Trials. Cancer, 71, 2163-8. https://doi.org/10.1002/1097-0142(19930315)71:6+<2163::AID-CNCR2820711607>3.0.CO;2-W
- Doval DC, Sharma A, Sinha R, et al (2015). Immunohistochemical profile of breast cancer patients at a tertiary care hospital in New Delhi, India. Asian Pac J Cancer Prev, 16, 4959-64. https://doi.org/10.7314/APJCP.2015.16.12.4959
- Dowsett M, Dunbier A (2008). Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res, 14, 8019-26. https://doi.org/10.1158/1078-0432.CCR-08-0974
- Gullick WJ (1990). New developments in the molecular biology of breast cancer. Eur J Cancer, 26, 509-510. https://doi.org/10.1016/0277-5379(90)90026-P
- Hartmann LC, Ingle JN, Wold LE, et al (1994). Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer, 74, 2956-63. https://doi.org/10.1002/1097-0142(19941201)74:11<2956::AID-CNCR2820741111>3.0.CO;2-V
- Hu P, Margolis B, Skolnik EY, et al (1992). Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors. Mol Cell Biol, 12, 981-90. https://doi.org/10.1128/MCB.12.3.981
- Ji H, Lipponen P, Aaltomaa S, et al (1993). c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer. Anticancer Res, 13, 1147-52.
- Klijin JGM (1991). Clinical parameters and symptoms for the progression to endocrine independence of breast cancer. In: mechanisms of progression to hormone-independent growth of breast and prostatic cancer. Carnfoth: The Parthenon Publishing Group, 11-9.
- Kurebayashi J (2007). Current clinical trials of endocrine therapy for breast cancer. Breast Cancer, 14, 200-214. https://doi.org/10.2325/jbcs.954
- Lehrer S, Lee P, Tartter P, Shank B, et al (1995). Breast cancer and family history: a multivariate analysis of levels of tumor HER2 protein and familyhistory of cancer in women who have breast cancer. Mt Sinai J Med, 62, 415-8.
- Mirtavoos Mahyari H, Khosravi A, Mirtavoos Mahyari Z, et al (2014). Overexpression of HER2/neu as a prognostic value in iranian women with early stage breast cancer; a single institute Study. Iran Red Crescent Med J, 16, 16005.
- Mohammadi S, Sulaiman S, Koon PB, et al (2013). Association of nutritional status with quality of life in breast cancer survivors. Asian Pac J Cancer Prev, 14, 7749-55. https://doi.org/10.7314/APJCP.2013.14.12.7749
- Qin T, Yuan ZY, Peng RJ, et al (2015). Clinicopathologic characteristics and prognostic factors for HER2 positive patients with metastaticbreast cancer in southern China. Arch Med Sci, 11, 544-50.
- Payandeh M, Sadeghi M, Sadeghi E, et al (2015). Clinicopathology figures and long-term effects of tamoxifen plus radiation on survival of womenwith invasive ductal carcinoma and triple negative breast cancer. Asian Pac J Cancer Prev, 16, 4863-7. https://doi.org/10.7314/APJCP.2015.16.12.4863
- Perou C, Sorlie T, Eisen M, et al (2000). Molecular portraits of human breast tumours. Nature, 406,747-52. https://doi.org/10.1038/35021093
- Perren TJ(1991). c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer, 63, 328-32. https://doi.org/10.1038/bjc.1991.78
- Olszewski WP, Szumera-Cieckiewicz A, Piechocki J, et al (2009). The characteristics of the sentinel lymph node metastasis in predicting the axillary lymph node status in patients with breast carcinoma. Pol J Pathol, 60, 138-43.
- Seshie B, Adu-Aryee NA, Dedey F, et al (2015). A retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana. BMC Clin Pathol, 15, 14. https://doi.org/10.1186/s12907-015-0014-4
- Sotiriou C, Neo S, McShane L, et al (2003). Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA, 100, 10393-8. https://doi.org/10.1073/pnas.1732912100
-
Yan J, Liu XL, Han LZ, et al (2015). Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-
${\alpha}$ expression in invasive ductal breast cancer patients and correlations with prognosis. Asian Pac J Cancer Prev, 16, 823-9. https://doi.org/10.7314/APJCP.2015.16.2.823 - White J, Morrow M, Moughan J, et al (2003). Compliance with breast conservation standards for patients with early stage breast carcinoma. Cancer, 97, 893-904. https://doi.org/10.1002/cncr.11141